Eli Lilly posted a 125% jump in Mounjaro revenue to $8.66 billion last quarter and raised full-year revenue guidance to $82 billion to $85 billion. The company’s market cap now stands at roughly $881.8 billion, underscoring strong fundamental momentum in its diabetes/obesity franchise. The update is materially positive for LLY and could support the shares, though it is company-specific rather than market-wide.
Eli Lilly posted a 125% jump in Mounjaro revenue to $8.66 billion last quarter and raised full-year revenue guidance to $82 billion to $85 billion. The company’s market cap now stands at roughly $881.8 billion, underscoring strong fundamental momentum in its diabetes/obesity franchise. The update is materially positive for LLY and could support the shares, though it is company-specific rather than market-wide.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.78
Ticker Sentiment
